Personalised Medicines & Biomarkers 2015
Offering our customers the knowledge and connections for a profitable business
  • Jennifer Shen

    Jennifer Shen FDA CDRH (USA)

  • Anka G. Ehrhardt

    Anka G. Ehrhardt Bristol-Myers Squibb

  • Claudio Carini

    Claudio Carini Pfizer (USA)

  • Suzanne Jenkins

    Suzanne Jenkins AstraZeneca

  • Sumit Munjal

    Sumit Munjal Takeda

  • Malcolm I Mitchell

    Malcolm I Mitchell Eli Lilly

  • Richardus Vonk

    Richardus Vonk Bayer

  • Celine Pallaud

    Celine Pallaud Novartis Oncology

  • Phillip Eichorn

    Phillip Eichorn Pfizer

  • Michael Merz

    Michael Merz Novartis

  • Mohammad Afshar

    Mohammad Afshar Ariana Pharma

  • Steinar Madsen

    Steinar Madsen Norwegian Medicines Agency

  • John Lambert

    John Lambert PAREXEL International

  • Darren Hodgson

    Darren Hodgson AstraZeneca

  • Chris Harbron

    Chris Harbron Roche

  • G. Narayanan

    G. Narayanan NDA

  • Andreas Wallnoefer

    Andreas Wallnoefer University of Basel

  • Chris Redhead

    Chris Redhead Comprehensive Biomarker Center

  • Philipp Schatz

    Philipp Schatz Metanomics Health

  • Peter Demant

    Peter Demant Roswell Park Cancer Institute

  • Lincoln Tsang

    Lincoln Tsang Arnold & Porter

  • Mohamed Oubihi

    Mohamed Oubihi YAKUMED

  • Jochen Theis

    Jochen Theis InHeCon

  • Andreas Benesic

    Andreas Benesic MetaHeps

  • Hans Lehrach

    Hans Lehrach Max - Planck Institute for Molecular Genetics

  • Stephen Pennington

    Stephen Pennington University College Dublin

  • Gary Middleton

    Gary Middleton University of Birmingham

  • Maria Hernandez Fuentes

    Maria Hernandez Fuentes King's College London

  • Liz Fuller

    Liz Fuller Bird & Bird

  • John Wise

    John Wise Pistoia Alliance

  • Iain D. Miller

    Iain D. Miller Healthcare Strategies Group

  • Marie Manley

    Marie Manley Bristows

02nd & 03rd December, Pestana Chelsea Bridge Hotel, London UK

“Strategies & Developments in Personalised Medicines & Biomarkers”

Sponsors & Exhibitors
  • Sponsors
  • Conference Info
  • Day One
  • Day Two
  • Speakers
  • Sponsors
  • Partners
  • Sponsorship Opportunity
  • Delegates
  • Pricing
  • Venue
  • Testimonials
  • Presentations
  • Gallery


With the onset of the genomic era and increase in clinical molecular analysis, more and more, clinicians and researchers are clearly defining multiple disease subtypes for diseases that were once thought to be singular in cause. This is opening the door to the discovery and development of highly effective and targeted diagnostics and therapies that result in better patient outcomes and the reduction in use of generalised treatments with severe side effects. Despite these benefits the regulatory and financial systems are not yet in place to enable this revolution in healthcare to flourish and there are many hurdles to overcome before Personalised medicine can become commonplace. 

At this conferfence, you will benefit from the expert knowledge of leaders into omics and disease research who are currently working towards a future where medical interventions are more precise, more targeted and are resulting in better patient outcomes. You will hear from those that are currently discovering and developing therapies, with companion diagnostics, and from the professionals who are responsible for personalised medical products that have already hit the market. There will also be discussions involving industry and regulatory bodies on the improvements and challenges of personalised medicine and its practical impact on the future of healthcare.
The global biomarkers market showcases high growth potential in the near future with an estimated CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018. Current industry trends such as advancements in discovery technologies, government initiatives, and grants for biomarker research activities, and the rising demand for Personalised medicine are the key factors that contribute to the growth of this market. However, the need for high capital investment for biomarker discovery, low benefit-cost ratio, a cumbersome biomarker validation, and testing process are a few of the critical factors that restrain the growth of the market. Biomarker professionals will gather together to answer the all-important question- how can we get biomarkers to add value? How do you develop new medicines, which demonstrate real value through predictable outcomes in targeted patient groups? The event is a 2-day strategic conference tackling these questions and providing participants with a thorough review of the use of biomarkers, their effectiveness and their potential to transform R & D.
It gives us immense pleasure in welcoming you to “Personalised Medicines & Biomarkers 2015''


  • Visionaries of Personalised Medicine
  • Biomarker discovery & validation - Government policies & strategies
  • Personalised Medicine in the USA,EU
  • Novel Applications for personalised medicine
  • Changing the business model to integrate personalised medicine
  • Can we streamline the commercialization process?
  • Discovering successful business models - Opportunities & Challenges
  • Learn about the latest findings in genomics and how to apply them to your practice
  • Learn practical applications for integrating genomics and pharmacogenomics to individualize patient care
  • Development and application of clinical safety biomarkers with a focus on imaging biomarkers
  • Discuss strategies to overcome obstacles of implementing genomic sequencing for patient care
  • Discuss how to disseminate genomic information to patients through ethical, legal and regulatory frameworks
  • Companion diagnostics & Personalised medicine
  • Technology & Point of Care
  • Safety & Biomarkers in clinical development - How biomarkers can accelerate your clinical development
  • Enabling technologies to maximise biomarker identification
  • Design strategies for success in early phase trials
  • Inflammatory / Immunological, Neurological, Oncology Biomarkers
  • Showing clinical utility of biomarkers to improve diagnosis & make informed decision making
  • See how improvements in technologies are leading to better efficiency of biomarkers
  • Analyze biomarkers and their role in drug development
  • Assess preclinical safety considerations
  • Identifying current developments in biomarkers & ways to overcome threats
  • Emerging stratified medicine via successful partnerships
  • Network in our combined exhibition and catering area
  • Evening networking reception for all attendees


 Senior attendees from leading pharmaceutical, biopharmaceutical, biotechnology, diagnostics, academics, government, CRO and solution provider companies will be attending. Meet Senior VPs, Directors, and Managers with the following categories:

  • Pharmaceutical Company Leaders
  • Personalised Medicines, Precision Medicines, Translational Medicines
  • Diagnostic/Analytics Company Leaders
  • Biotechnology
  • CRO
  • Medical/Diagnostics Laboratories, Consulting, Biobanks
  • Genome Interpretation Experts
  • Genome Sequencing Pioneers
  • Biotech Leaders
  • Healthcare Providers
  • Consultants
  • Doctors & Pharmacists
  • Government Leaders
  • Health Insurance Executives
  • Investors
  • Biomarkers Pharmacogenomics
  • Oncology
  • Molecular Biology
  • Epigenetics
  • Clinical Pharmacology Statistical Biomarkers
  • Clinical Oncology
  • Proteomics
  • Discovery Medicine
  • Clinical and Translational Research
  • Experimental Medicine
  • Systems Biology
  • CNS
  • Toxicity
  • Regulation
  • PK/PD
  • Genomic 
  • Pharmacogenetics
  • Molecular Informatics 
  • Neurology 
  • MicroRNA
  • Imaging


Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. You cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway.  Devise an immediate action plan for your strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

08:30 – Coffee and registration


09:30 – Morning Chairperson opening remarks  

IAIN D. MILLER, Founder, Healthcare Strategies Group


09:40 – Keynote Address Clinical Biomarkers 101: The logistics of quality

  • Using drastic data on failed collaborator performance
  • Illustrate the importance of close collaboration and fit-for-purpose quality supervision
  • Derive a practical solution and show dramatic results of realistic innovation

ANKA G. EHRHARDT, Director Clinical Cytometry, Biomarker Technologies, ECTR, Bristol-Myers Squibb 


10:10 Large-scale precompetitive collaboration: key to successful safety biomarker qualification

  • Safety biomarkers: burning needs and crucial gaps
  • Key challenges for clinical biomarker qualification
  • The IMI SAFE-T consortium: scope, outcome, lessons learned
  • Future research efforts

MICHAEL MERZ, Director of Preclinical Safety, Novartis 


10.40 – Keynote Panel Discussion - Personalised Medicines – Opportunities & Challenges

  • Overview on patentable subject matter in connection with Personalised medicine
  • Challenges arising when it comes to the enforcement of Personalised medicine patents
  • Challenges and Opportunities for commercializing personalised medicine
  • Overcoming barriers to access and understanding value: Patient access to innovative therapies
  • Can Personalised medicine improve clinical outcomes?


Moderator –

IAIN D. MILLER, Founder, Healthcare Strategies Group


Panelists –

SUMIT MUNJAL, Medical Director, Takeda  

PHILIPP SCHATZ, Head of Biomarker Program, Metanomics Health

GARY MIDDLETON, Professor of Medical Oncology, University of Birmingham

PETER DEMANT, Distinguished Member and Professor, Roswell Park Cancer Institute

11:20 – Morning Coffee & Networking 


11:40 – Beyond Pharmacokinetics and Pharmacodynamics – New Genetics of Cancer Chemotherapy

  • Standard doses of chemotherapy leave a large proportion of patients over-treated or under-treated
  • PK/PD-based markers fail to identify most of them
  • We detected in mouse model numerous novel non-PK/PD genes that determine
    drug toxicity and describe their action

PETER DEMANT, Distinguished Member and Professor, Roswell Park Cancer Institute 


12:10 – The route to biomarkers with medical utility - The role of statistics

  • Early identification of biomarker
  • From qualitative to quantitative decision making
  • Application of advanced statistical methods – preparing results for later phases
  • Patient selection and enrichment designs – cheaper, faster, better?

RICHARDUS VONK, Head of Research & Clinical Sciences Statistics, Bayer


12:40 Networking luncheon 


13:50 – Panel Discussion: Oncology - A frontrunner position in personalising medicine.

  • Insight into tumor biology, in technologies and in treatment strategies that pave the way for a precision treatment tailored to both patient and tumor
  • What are the latest developments? 
  • Can we predict whether a person will respond to a certain therapy? 
  • How does Personalised cancer treatment contribute to patient survival and quality of life? 
  • How can the pharmaceutical industry help?


 Moderator –

JOCHEN THEIS, Owner & Principal Consultant, InHeCon          


 Panelists –

CELINE PALLAUD, Sr. Dir, Global Correlative Sciences Leader, Novartis Oncology

ANKA G. EHRHARDT, Director Clinical Cytometry, Biomarker Technologies, ECTR, Bristol-Myers Squibb


CHRIS REDHEAD, CBC Corporate & Business Development, Comprehensive Biomarker Center 


14:30 – Emerging commercial paradigm for personalised medicine: Recent developments and EU market access

  • Market access in the EU and UK
  • Recent developments in the field of Personalised medicines 
  • In an environment of constrained spending, how can these innovations evolve into successful business models?

IAIN D. MILLER, Founder, Healthcare Strategies Group


15:00 – Multi component biomarker signature for drug development and treatment selection

  • Challenges developing Multi Analyte Algorithmic diagnostic Tests (MAAT)
  • Illustration of the over fitting issue when number of samples is orders of magnitute smaller than the quantity of information for each sample.
  • Real life examples:  ExtempoNMR- real time metabolomic cancer diagnostics and onco KEM therapeutic decision support systems



15:30 Afternoon Coffee & Networking  


15:50 Metabolic biomarker based diagnostics for heart failure and pancreatic cancer

  • Metabolite data enables discovery of new biomarker for diagnostics
  • Leverage metabolite profiling results to validated biomarkers
  • Current limitations of established heart failure diagnosis and how to overcome these
  • Combination of established clinical markers (e.g. NT proBNP or CA19-9) with new metabolic signature applying cutting-edge biostatistics for an improved diagnosis.
  • Transfer form metabolic discovery to clinical routine platform

PHILIPP SCHATZ, Head of Biomarker Program, Metanomics Health

16:20 – Biomarkers of Idiosyncratic drug-induced liver injury (iDILI): need for improved causality assessment

  • The Challenge of Idiosyncratic drug-induced liver injury (iDILI)
  • Biomarkers in iDILI: an unmet medical need
  • Strategies for iDILI biomarkers
  • Novel technologies to enable iDILI biomarker develeopment


16:50 Chairperson’s closing remarks and end of conference.

IAIN D. MILLER, Founder, Healthcare Strategies Group


17:00 – 18:00 – Networking Drinks Session

08:30 – Coffee and registration


09:30 – Morning Chairperson opening remarks 

JOHN WISE, Executive Director Business Development, Pistoia Alliance  


09:40 – Keynote Address – Companion diagnostics

  • Exploring how diagnostics companies/developers of biomarkers and labs are working with drug developers 
  • How to bring to market new companion diagnostics and targeted therapies to ensure greater efficacy and thus better patient outcomes.
  • What are the real-world challenges to successful adoption of molecular/companion diagnostics?

SUZANNE JENKINS, Diagnostics Expert (Director), Personalised Healthcare & Biomarkers, AstraZeneca 


10:10 – Development and delivery of blood based multiplexed protein biomarker tests for patient treatment decision-making: Prostate cancer case study

  • Proteomics-based protein biomarker discovery has not yielded many clinically used biomarker tests. Why?
  • About 1 in 7 men get diagnosed with Prostate Cancer and most of these would benefit from not being treated.
  • Deciding who to treat (or not) remains very challenging and over treatment is therefore common.
  • The discovery and on-going development of a blood multiplexed protein test - OCProDx - to support clinical decision making will be outlined.
  • Potential strategies for the delivery and implementation of the test will be introduced.

STEPHEN PENNINGTON, Professor of Proteomics School of Medicine & Medical Science, UCD Conway Institute, University College Dublin


10.40 – Keynote Panel Discussion: Biomarkers Challenges and Opportunities

  • Bringing biomarkers to culmination: are we realising its prospects?
  • Challenges and Opportunities for biomarker enterprises
  • Imaging as a powerful biomarker in drug development
  • Scientific & operational challenges & successes in biomarker development & utilisation
  • Disruptive innovation and emerging technologies – future prospects for biomarkers
  • The impact of biomarkers on personalised medicine and clinical practice


Moderator –

JOHN WISE, Executive Director Business Development, Pistoia Alliance 


Panelists – 

ANDREAS WALLNOEFER, Head Personalized Health & Translational Medicine, University of Basel

MARIA HERNANDEZ FUENTES, Senior Lecturer in Translational Research, King´s College London

JOHN LAMBERT, Chief Medical Officer Early Phase, PAREXEL International  


11:20 – Morning Coffee & Networking


11:40 – Precision Medicine: Are We There Yet?

CLAUDIO CARINI, Global Head of Clin. Immunology & Biomarkers, Pfizer (USA) 


12:10 – Japanese Pharmaceutical Market - Pharmacogenomics and Biomarkers in Japan 

MOHAMED OUBIHI, Founder and Managing Director, YAKUMED


12:40 Networking luncheon


13:50 – Design strategies for success in early phase trials

  • Simulation approaches to optimize success 
  • Effective clinical trial design with a focus on biomarker related statistics
  • Increase use of Pharmacometrics
  • Improving decision making through design. 
  • Minimizing missing data and consequences of avoiding issues. 
  • Utilization of Biomarkers in early clinical drug development
  • Adaptive Design 


Moderator –

JOHN WISE, Executive Director Business Development, Pistoia Alliance 


Panelists –

DARREN HODGSON, Senior Principal Translational Scientist, Oncology iMED, AstraZeneca

CHRIS HARBRON, Principal Statistical Scientist, Roche 

MALCOLM I MITCHELL, Senior Medical Fellow, Clinical Pharmacology, Eli Lilly 


14:30 – Panel Discussion: Personalised Medicines & Biomarkers Recent legislative and regulatory developments

  • Considerations for successful registration of a drug and diagnostic – a roadmap and key interactions
  • Regulatory threshold for product approval 
  • Regulatory & Reimbursement Trends in biomarker development
  • What are the impacts of recent regulatory qualification processes having on collaborative efforts to develop and qualify new biomarkers?
  • What is to be learnt on how companies can work in harmony with the RoW legal frameworks?
  • Keep abreast with the changing International regulations of personalised medicines
  • Should there be any additional biomarker qualification acceptance paths be developed?


Moderator –

G. NARAYANAN, Managing Director, Biologicals Advice, Biologics and Advanced Therapies Expert, NDA


Panelists –

PHILLIP EICHORN, Senior Director (Worldwide Safety and Regulatory), Pfizer 

LINCOLN TSANG, Partner, Arnold & Porter 

LIZ FULLER, Partner, Bird & Bird

MARIE MANLEY, Partner & Head of the Regulatory Practice, Bristows


15:10 – Personalised medicines – a regulatory and economical nightmare?

STEINAR MADSEN, Medical director - Department of Drug Information, Norwegian Medicines Agency 


15:40 – Afternoon Coffee & Networking


16:00 Personalisation of therapy-virtualisation of drug development: Two sides of the same coin

  • Personalisation is not stratification
  • How far will stratification get us? Where do we need real personalisation? Etc…..
  • The need for virtualisation in drug development
  • The potential of new approaches to go far

HANS LEHRACH, Director, Max-Planck Institute for Molecular Genetics

16:30 – Recent Developments in Companion Diagnostics – (Virtual Presentation) 

JENNIFER SHEN, Senior Scientific Reviewer in the Division of Molecular Genetics and Pathology, FDA CDRH (USA)


17:10 – 17:20 Chairperson’s closing remarks and end of conference.

JOHN WISE, Executive Director Business Development, Pistoia Alliance

Jennifer Shen

Senior Scientific Reviewer in the Division of Molecular Genetics and Pathology


Dr. Jennifer Shen received her PhD in molecular biology from the University of California, San Francisco in 2003, followed by a postdoctoral fellowship at the National Cancer Institute in NIH.  Dr. Shen has published a number of scientific research papers in journals such as Cancer Research, Clinical Cancer Research, PLoS ONE, and Endocrine-related Cancer.  Following her postdoctoral fellowship, Dr. Shen spent 2 years as a NCI-FDA fellow at the Center for Drug Evaluation and Research (CDER) in FDA.  At CDER, she worked at different review disciplines (i.e., clinical pharmacology, pre-clinical pharmacology/toxicology, and CMC) to gain understanding on oncology drug regulatory process.  Dr. Shen joined CDRH/OIR in 2011 as a scientific reviewer.  Since then, Dr. Shen has actively involved in reviews and approvals of companion diagnostics devices.b

Anka G. Ehrhardt

Director Clinical Cytometry, Biomarker Technologies, ECTR

Bristol-Myers Squibb

Dr. Anka Ehrhardt is a biophysicist with a doctorate in physiology.  She is currently working in the United States for Bristol-Myers Squibb.
Previously, Dr. Ehrhardt headed a technology laboratory at Merck, covering comprehensive instrumentation in high tech fields such as fluorescence, imaging, flow cytometry, electrophysiology and luminescence for the entire range from early discovery to late stage clinical trials across all disease areas.
In her current position at BMS, Dr. Ehrhardt directs the Clinical Cytometry, covering a large portfolio across disease area clinical studies. Her work focuses on biomarkers as tools to drive the development of urgently needed new medicines.  This includes optimizing biomarkers to gather clear data driving fast well founded decision making, and maximizing the information gathered from clinical samples to support hypothesis generation.
Dr. Ehrhardt is on the board of directors of different industry organizations, fostering innovation and collaboration between industry, academia and government organizations.

Claudio Carini

Global Head of Clin. Immunology & Biomarkers

Pfizer (USA)

Leads biomedical research in the area of inflammation and personalized medicine. Studied Medicine in Italy and trained in internal medicine and clinical immunology. Completed PhD in Immunology at the University College London (UCL), London. Completed membership of the Royal College of Pathologists, London and Specialist Diplomas in Clinical Immunology and Respiratory Medicine, School of Medicine, Rome.

Presently is the Global Head Clinical Immunology and Biomarkers at Pfizer and a Hon. Faculty at King’s College, School of Medicine, London.  Held faculty positions at Harvard, Johns Hopkins, UCL, Rome and senior roles at Wyeth, Novartis, and Roche.

Presently serving in national and international scientific boards:

F-NIH Biomarkers Consortium “Inflammation & Immunology” Steering Committee

F-NIH Biomarkers Consortium “RA Working Group” Steering Committee

F-NIH Biomarkers Consortium “SLE Working Group” Steering Committee

F-NIH Biomarkers Consortium “Ankylosing Spond.Working Group” Steering Committee

MRC, (UK “Inflammation/ Immunology Initiative - UK RA Consortium, Steering Committee

MRC, (UK) “Stratified Medicine, SLE Consortium, Steering Committee

Biomarkers Development Center, NL, Advisory Board

IMI, ABIRISK, European Union/EFPIA” Board of Directors

The PML Consortium, Board of Directors

Research interests include understanding the role of biomarkers and precision medicine in autoimmune diseases

Published widely in areas of immunology and molecular medicine. Over 200 publications in national and international peer reviewed journals.

Suzanne Jenkins

Diagnostics Expert (Director), Personalised Healthcare & Biomarkers


Dr Jenkins has more than 15 years experience in the pharmaceutical industry, working in discovery genetics, pharmacogenetics and most recently as a companion diagnostics expert within the Personalised Healthcare & Biomarkers function at AstraZeneca.  Her current role involves partnering with Roche Molecular Systems to lead the development of a companion diagnostic for AstraZeneca’s AZD9291, an EGFR TKI which has been granted Breakthrough Therapy designation by the US FDA.

Suzanne holds a Bachelor of Science (BSc Hons) degree in Applied Biological Sciences from the University of the West of England and Doctor of Philosophy (DPhil) degree in Immunogenetics from the University of Oxford.

Sumit Munjal

Medical Director


Dr Sumit Munjal, a physician by training and an Indian by background has been associated with

Academic organizations such as London School of Hygiene & Tropical Medicine, Faculty of Pharmaceutical Medicine of the Royal College of Physicians and DSRU Southampton;

Government organizations such as NHS UK and MHRA;

And Pharmaceutical industry such as Johnson & Johnson, Millennium Oncology Pharmaceuticals Inc, Nycomed and Takeda Pharmaceuticals.

He is keen and remains committed to promote public health, patient safety and meet healthcare needs around the globe. He is currently based out of Central London.

Nov 2015, Dr Sumit Munjal

Malcolm I Mitchell

Senior Medical Fellow, Clinical Pharmacology

Eli Lilly

Malcolm Mitchell is a graduate of Newcastle Medical School, following a decade in the NHS ,  he joined the pharmaceutical industry over 30 years ago, with positions in Pfizer, NAPP and Lilly.  He has been working in  clinical pharmacology at  Eli Lilly for the past 20 years.  He has been involved  in ongoing drug development for many aspects of clinical pharmacology through the portfolio. This includes most of the studies performed from FIH through to BE for formulation change, working with both small molecule NCEs and biologicals.

The extensive changes over the years in expectations of results from FIH studies has been a focus.

Richardus Vonk

Head of Research & Clinical Sciences Statistics


Dr. Richardus Vonk is senior director and head of Research and Clinical Sciences Statistics at Bayer Pharma AG in Berlin, Germany. He has about 25 years of experience in research and pharmaceutical development. His current scientific interest is in statistical method
development for early pharmaceutical research and the transition between research and
clinical development. He leads a team of biostatisticians who focus on statistical support to
discovery and pre-clinical safety programs and early clinical development. This includes the
statistical support of pharmacogenomic and pharmacogenetic studies and biomarker
Dr. Vonk has an MSc in Mathematics from the University of Nijmegen, and obtained his PhD
at the Free University Berlin.

Celine Pallaud

Sr. Dir, Global Correlative Sciences Leader

Novartis Oncology

Phillip Eichorn

Senior Director (Worldwide Safety and Regulatory)


Michael Merz

Director of Preclinical Safety


Dr. Michael Merz is a clinical pharmacologist by training, with his main focus on drug safety during the past ten years. He worked as phase 1 investigator and Head of Phase 1 clinic for Quintiles in Freiburg, Germany, and joined Novartis Pharma in Basel, Switzerland, as Clinical Pharmacology Expert in 1998. At Novartis, he assumed responsibility as Head of Modeling and Simulation in Clinical Pharmacology, worked as Senior Medical Safety Expert in Clinical Safety and Epidemiology, and led the Systems Toxicology Section in Preclinical Safety. He has set up the company’s liver expert team in 2008 and has been leading the group since then. In addition, Dr. Merz is the project coordinator for the European Union’s IMI SAFE-T consortium, focusing on clinical qualification of liver, kidney, and vascular safety biomarkers.

Mohammad Afshar


Ariana Pharma

Mohammad Afshar is the founder and CEO of Ariana® Pharma, a leading decision support company bringing the benefits of Big Data to clinicians. Specialized in patient stratification and design of multiplexed biomarkers, over the last 10 years Ariana has developed diagnostic and software tools that help clinicians choose the best personalized treatment for the right patient. Prior to joining Ariana in 2003, Mohammad was a founder and the Director of Drug Design at RiboTargets, Cambridge, UK. He set up and managed the structure-based discovery platform which successfully licensed novel therapeutic molecules. Before joining RiboTargets Mohammad held several positions in academic institutions including the Department of Chemistry of the University of York, UK, and the CRBM of the CNRS in France. He holds a Medical Degree (DCEM), MPhil in Computer Science (DEA), a PhD in structural biochemistry and a "Habilitation doctorate" (HDR) from the Faculty of Medicine of the University of Montpellier, France.

Steinar Madsen

Medical director - Department of Drug Information

Norwegian Medicines Agency

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency, where he has almost 20 years of experience. Among others, his tasks at the Agency are drug information including safe use of drugs and pharmacovigilance. He is a specialist in internal medicine and cardiology and works part time as a consultant.

John Lambert

Chief Medical Officer Early Phase

PAREXEL International

Dr Lambert provides a broad range of expert consulting services to clients for early drug development. This includes the development of a clinical development plan with focus on time and cost savings; selection of compound specific biomarkers for early proof-of-mechanism; selection of compound specific safety parameters and preparation of relevant documents including the protocol and Investigator's Brochure.

Dr Lambert is Vice President, Chief Medical Officer and heads the Global Medical and Scientific Affairs and Consulting group for PAREXEL Early Phase. Prior to his current role, he worked for PAREXEL International as Senior Director and then Vice President PAREXEL Early Phase, London, United Kingdom (UK), for 8 years, and has been with the company since 2000. Dr Lambert is based in the London Early Phase Clinical Unit and provides additional medical and scientific oversight of studies including overseeing the safety of the study participants.

With more than 36 years' medical experience, Dr Lambert has worked in Australia, Canada and the UK, and he has over 17 years' experience working in CROs, holding positions including Director of  Medical Affairs and Chief Medical Officer. He has extensive clinical experience and is trained and certified in Internal Medicine, Gastroenterology, Pharmaceutical Medicine and Clinical Pharmacology. He has worked as Principal Investigator on over 80 clinical studies including new biologicals and biosimilars.

Among various industry affiliations, Dr Lambert is a member of the British Association of Pharmaceutical Physicians, American Gastroenterology Association, Fellow of the Faculty of Pharmaceutical Medicine, Member of the American College of Clinical Pharmacology and Fellow of  Royal Australian College of Physicians, in addition to being a member of other international associations.

He holds a MBBS and a MMed from the University of Melbourne; a PhD from Monash University, Melbourne; and a Dip Pharm Med from the University of Wales, Faculty of Pharmaceutical Medicine.

Dr Lambert has published extensively, including peer reviewed articles, abstracts, and book chapters.

Darren Hodgson

Senior Principal Translational Scientist, Oncology iMED


Darren is Senior Principal Translational Scientist, Oncology iMED at AstraZeneca having previously had positions in Global Medicines Development, academia, biotechnology and diagnostics sectors.  Darren has been responsible for strategy, internal and external assay development, clinical deployment and regulatory representation for biomarkers used as primary, secondary and exploratory objectives of clinical studies at all stages of drug development.  Most recently Darren was the Translational science lead for Lynparza, AstraZeneca’s first in class PARP inhibitor approved in 2014 for ovarian cancer indications in Europe and the US defined by loss of function mutations in tumour suppressor genes.  Darren is author of numerous reviews, original patents and papers, journal editor, chairman of the Manchester Consumer Healthcare Ethics committee and lectures at the Universities of Manchester and Leeds.

Chris Harbron

Principal Statistical Scientist


Chris Harbron is a Principal Statistical Scientist at Roche. Through a variety of roles within the pharmaceutical industry Chris has worked in all stages of the drug development pipeline from drug discovery to early and late development. He has a particular interest in the design and analysis challenges in the application and discovery of biomarkers both for Personalised HealthCare and for robust decision making. Chris has published and presented widely both within the statistical and the broader scientific literature.

G. Narayanan

Managing Director, Biologicals Advice, Biologics & Advanced Therapies Expert


Dr. Narayanan has substantial regulatory expetise in the area of biologics, advanced therapies and biosimilars. He worked at MHRA during 2001 – 2013 and was Head of the Biotechnology unit and Expert Medical Assessor. He was also member of the Committee for Advanced Therapies (EMA/CAT 2009 – 2013), Scientific Advice Working Party (CHMP/SAWP 2009 - 2013), Biosimilar Working Party (EMA/BMWP) and Gene Therapy Working Party. He is Biologics and Advanced Therapies expert at NDA Regulatory Science. He is also Managing Director of Biologicals Advice Limited and provides independent advice on all aspects of development of medicinal products with a special interest in advanced therapies. He is on the scientific editorial board of Gene Therapy Clinical Development journal. He previously worked at Reckitt Benckiser, UK and Chiron Corporation, CA, USA. He has dual specialist postgraduate qualification in general internal medicine and pharmaceutical medicine.

Andreas Wallnoefer

Head Personalized Health & Translational Medicine,

University of Basel

Andreas joined F. Hoffmann-La Roche after his clinical research fellowship at the University of Leiden in the Netherlands. At Roche he was initially responsible for Clinical “Proof of Concept” studies and later took on the leadership for several Clinical Development programs. In 2012 he was appointed as Global Head of Exploratory Development.
In 2007, he became Global Head of Clinical Research & Exploratory Development. Under his leadership Discovery Research and Clinical Research became better connected and translational medicine became a key driver to implement the Personalized Healthcare strategy of Roche.

As a Senior Vice President, Andreas became the task force leader for the integration of the clinical development departments of Roche and Genentech. After the Genentech acquisition he was appointed 2010 as the new Head of Roche pRED Development. In 2012 he took on, in addition, the role of the Head of the Cardiovascular & Metabolism Disease (CVM) Discovery and Clinical Research. In 2014 Roche decided to exit CVM. After managing the re-structuring, Andreas decided to complete his Executive MBA at IMD Lausanne, a world leading business school and to conduct a sabbatical with the Universities of Leiden and Zürich with focus on innovation transfer and industry/academia partnerships. Subsequently, in summer 2015, Andreas accepted to join the University of Basel as Head of Personalized Health and Translational Medicine in collaboration with the ETH and University of Zurich, Switzerland.  He remains associated with the University of Leiden and chairs 2016 the Singapore ASTAR scientific advisory board.

Chris Redhead

CBC Corporate & Business Development

Comprehensive Biomarker Center

Following an early career as a cell biologist, Chris spent more than 12 years providing ranked equity research on leading UK/European small and midcap biopharmaceutical, healthcare and diagnostic companies. A founding partner of the life science investment banking boutique Code (subsequently Nomura Code) Securities, Chris founded Aruwon in 2009 to provide corporate and business development advice to diagnostic and biopharma companies worldwide.  Chris has been working with CBC on its corporate and business development strategy since 2014.

Philipp Schatz

Head of Biomarker Program

Metanomics Health

Philipp Schatz, Ph.D., is Head of Biomarker Program at the Metanomics Health GmbH a BASF company. He oversees the biomarker program which provides metabolic biomarkers to support pharma-enabling and diagnostic applications in various indications such as, congestive heart failure, type 2 diabetes, neurodegenerative diseases and multiple oncological applications. Prior to Metanomics Health, Dr. Schatz worked for 12 years in the diagnostic industry. He was with the Epigenomics AG with various responsibilities.  Dr. Schatz holds a M. Sc. in Biotechnology Engineering from the Technical University Berlin and a Ph.D. in epigenetics from the University of Saarland.

Peter Demant

Distinguished Member and Professor

Roswell Park Cancer Institute

Dr. Demant has used mouse genetics to provide important contribution to understanding several biological aspects of cancer and immunology. The latter included discovery of novel histocompatibility genes, demonstration of complement genes inside the major histocompatibility complex, and functional dissection of immune responses to parasite infections. In his research on cancer he was first to detect, map, and identify a cancer susceptibility gene, and map more than 50 novel cancer susceptibility genes. This allowed him to demonstrate epistatic effects of cancer susceptibility genes, and show trans-organ effects, and describe genetic control of lymphocyte infiltration in tumors. His recent work concentrates on host and tumor responses to anti-cancer chemotherapy.

After obtaining MD and PhD in Prague, Czechoslovakia, he worked as postdoc with Dr. G. D. Snell (Nobel Prize for histocompatibility) and since 1976 worked at The Netherlands Cancer Institute in Amsterdam, The Netherlands, as Head of Subdivision of Genetics in Division of Molecular Genetics and subsequently as Head of the Division. Presently he works as a Distinguished Member and Professor at The Roswell Park Cancer Institute in Buffalo, New York.

Lincoln Tsang


Arnold & Porter

Lincoln Tsang is a partner based in the London office of Arnold & Porter, an international law firm. He specializes in dealing with complex regulatory, compliance and enforcement matters. He was a senior official at the UK regulatory agency for 13 years and lately as head of biologics. He served as an advisor to the European Commission, European Directorate for the Quality of Medicines, Council of Europe and the World Health Organization. He was a board member of the National Institute for Biological Standards and Control. He is appointed by Health Ministers to serve as a Commissioner of the British Pharmacopoeia Commission where he chairs the biologicals and biotechnology committee and the nomenclature committee.

Mohamed Oubihi

Founder and Managing Director


Dr. Mohamed Oubihi is an Expert in Pharmaceutical Regulatory and Business Development. He has 15 years global experience covering Japan, Europe and Emerging Markets.

Mohamed has worked for several global pharmaceutical and biotech organizations in various capacities: R&D, Regulatory Affairs, Business and Drug Development areas.

In his position with Novo Group, he was Vice Chairman of Japanese Association of Enzyme Additives. In 2007 Mohamed joined Biogen Idec in the UK to lead the company’s expansion into Japanese market.

From 2010 Mohamed was appointed as EU regulatory drug development lead for Biogen whilst still advising the organization on Japan and Asia Pacific Strategy. Mohamed has led advocacy efforts of Biogen Idec in Europe and Japan on several global industry initiatives.

In his position with Abbott/Abbvie, Mohamed Mohamed was directing Regulatory Strategy group covering Japan and Asia Pacific.

From October 2013, Mohamed founded YAKUMED Ltd, a niche consultancy focused on Japanese and MENA market. Since its inception YAKUMED has provided professional strategic and operational support to a dozen of European, US and Japanese pharmaceutical and Biotech companies in the areas of Drug Development and Business Development.

Jochen Theis

Owner & Principal Consultant


Jochen Theis, MD FFPM is a physician scientist providing consultancy services to pharma, biotech, diagnostic and venture capital companies, primarily in the areas of innovative clinical drug development, translational medicine, and personalized healthcare. In addition to running his own consultancy he currently serves as Chief Medical Advisor at Kymab in Cambridge.

Prior to founding his own consultancy, Jochen Theis held industry positions of increasing responsibility at Boehringer Ingelheim, GSK, and Roche up to VP level.

Jochen Theis trained in pediatrics in Marburg, Germany, and Manchester, United Kingdom, and served as a clinical and research fellow in pediatric and perinatal pharmacology and toxicology at the Hospital for Sick Children in Toronto, Canada. He is a certified specialist in clinical pharmacology and has retained active links with academia throughout his career holding teaching responsibilities at the University of Toronto and at the University of Cambridge. He currently is an Honorary Professor in Pharmaceutical Medicine at the University of Surrey.

Andreas Benesic



Following his study of medicine at the Julius-Maximilians-University of Wuerzburg and a training visit at the Royal North Shore Hospital, University of Sydney, Australia, Andreas Benesic obtained his MD degree in 2003. He worked as staff physician at the Dept. of Medicine, Univ. of Wuerzburg in the Dept. of Infectiology and Hepatology. From 2004 to 2006 he held a post doc position at the Institute of Physiology supported by a DFG grant.  In 2006 he joined the group of Professor Alexander L. Gerbes at the University of Munich. Since then he has been leading research projects on drug-induced liver injury. He is a member of the Munich liver transplantation program.

From the beginning of his academic career Andreas Benesic has focused his research on pathophysiology and toxicology of food contaminants and drugs, starting with research on nephrotoxicity of the food contaminant ochratoxin A. He performed research on side-effects of HAART in HIV-patients. Afterwards he investigated mechanisms of ifosfamide nephrotoxicity in human primary proximal tubule cells after obtaining personal funding by the DFG. From 2006 his research interest focused on drug-induced liver injury with emphasis on idiosyncratic reactions and possibilities to model these individual features in vitro. Together with Prof. Alexander L. Gerbes he has developed MetaHeps, a novel technology for diagnosis of DILI in individual patients. This research has been supported by grants from exist technology transfer (2012) and the m4 award for research innovation in personalized medicine (2014), respectively. Since 2014 Andreas Benesic is CEO and co-founder of the Martinsried based biotech start-up company MetaHeps GmbH. Aim of the company is to provide drug developers novel solutions for issues with liver toxicity in clinical phases of drug development.

Hans Lehrach


Max - Planck Institute for Molecular Genetics

Hans Lehrach obtained his Ph.D. at the Max Planck Institute for Experimental Medicine and the Max Planck Institute for Biophysical Chemistry in 1974. Next he moved on to Harvard University, Boston (1974-1978) for a postdoc and then became group leader at EMBL, Heidelberg (1978-1987). He then moved to the Imperial Cancer Research Fund, London (1987-1994) to become head of the Genome Analysis Department. In 1994 he returned to Germany to become Director at the Max Planck Institute for Molecular Genetics (since 1994, em. 2014).

His expertise lies in genetics, genomics, systems biology and personalized medicine. Highlights include his key involvement in several large-scale genome sequencing projects, such as the human, rat, and Schizosaccharomyces. His group was part of the team which identified the Huntington’s disease gene. Dr. Lehrach also performed key work on technologies such as protein microarrays, protein interactome analysis, yeast artificial chromosomes and RNAseq. He has been pioneer in the application of next generation sequencing techniques and systems medicine for the development of personalized therapies in cancer (Virtual Patient Model). He is partner in two German ICGC projects and partner in the European IHEC project BLUEPRINT, he is a steering committee member of the 1000 Genomes project, leader of the managing entity of the IMI OncoTrack project and co-ordinated the FET Flagship pilot initiative IT Future of Medicine (ITFoM).

Dr. Lehrach has founded several biotechnology companies such as Sequana Therapeutics, GPC Biotech, Scienion, Prot@gen, PSF Biotech, Atlas Biolabs. Dr. Lehrach is founder of the Berlin-based company Alacris Theranostics GmbH, specialising in the development of new approaches for personalised medicine for cancer patient diagnosis, treatment and drug stratification. He is chairman of the Supervisory Board and scientific advisor of the company since 2008. In 2010 he founded the non-for-profit research institute The Dahlem Centre for Genome Research and Medical Systems Biology (DCGMS).

Stephen Pennington

Professor of Proteomics School of Medicine & Medical Science, UCD Conway Institute

University College Dublin

Steve graduated from Imperial College of Science and Technology, University of London with a joint honours degree in Chemistry and Biochemistry before completing a PhD in Biochemistry at the University of Cambridge.  During his PhD he was awarded an Elmore Medical Research Fellowship and it was during this fellowship that his interests in protein mediated cell signalling and the regulation of the mammalian cell cycle began. Subsequently, he was Wellcome Lecturer in the University of Liverpool before moving to University College Dublin in 2003 where he is  Professor of Proteomics in the School of Medicine and the UCD Conway Institute of Biomolecular and Biomedical Research. He was a lead investigator in the Dublin based ‘Prostate Cancer Research Consortium’ and a member of the first Global Action Plan initiative launched by Movember. His research team (  work closely with clinical colleagues to use a range of proteomics platforms including label-free LC-MS strategies to discover protein biomarkers to meet specific unmet needs in oncology and inflammatory disease.  To progress these biomarkers to potential clinical diagnostic assays the team has established a dedicated laboratory for targeted multiplexed protein biomarker measurement and clinical evaluation by mass spectrometry.

Stephen has been awarded a Beit Memorial Fellowship and received a Sir Henry Wellcome Commemorative Award for Innovative Research. He serves on the editorial boards of several journals, and is currenty vice-president of the British Society for Proteome Research, a general council member of the European Proteomics Association and lead organizer of the forthcoming 2017 annual congress of the Human Proteome Organisation (HUPO) which will be held in Dublin.

Gary Middleton

Professor of Medical Oncology

University of Birmingham

Gary Middleton is Professor of Medical Oncology at the University of Birmingham. He is the Chief Investigator on the National Lung Matrix Study and is also Chief Investigator of PePS2, FOCUS4A, RUXSAC, TELOVAC, VIP and co-CI on TORCMEK. He sits on the Lung CSG, the NCRI advanced colorectal sub-group and the Experimental Medicine Expert Review Panel. His translational interests include tumour immunobiology and the tumour microenviroment with a principal focus on MDSCs and the somatic and germline drivers of an anti-cancer immune response.

Maria Hernandez Fuentes

Senior Lecturer in Translational Research

King's College London

Dr Hernandez-Fuentes studied Medicine in Universidad Complutense and then did a PhD in Immunology in Universidad de Alcalá, both in Madrid, Spain. In 1998 she moved to the UK to do a post-doc  at Hammersmith Hospital, Imperial College London, working on alloimmune responses. In 2005 the research group moved to King’s College London and she started leading the Biomarker research group of the MRC Centre for Transplantation. Since 20011 she is Senior Lecturer in Translational Research.

Dr Hernandez-Fuentes has a long standing interest in understanding and quantifying alloimune responses and immune monitoring in kidney transplantation; particularly looking at obtaining evidence of tolerance. Of late this has translated into focusing on the role of B lymphocytes in transplantation tolerance.

The Biomarker Research Team that is aiming to translate into the clinic Biomarkers that could be predictive of kidney transplant outcome and could eventually enable biomarker-lead individualisation of therapy. Within the team Genome Wide Association scans, gene expression and a number immune-monitoring techniques are used.

She has a degree on Teaching and Learning in Higher education and is a Fellow of the Higher Education Academy.

She was involved in the society of Spanish Researchers in the United Kingdom (SRUK/CERU) from its inception. She worked to obtain its official registration in 2012, she has been a member of the Board of Directors from the beginning and from July 2014 – July 2015 she has been the President of the society.

Liz Fuller


Bird & Bird

John Wise

Executive Director Business Development

Pistoia Alliance

John Wise is an Executive Director of the Pistoia Alliance and the Programme Co-ordinator for the PRISME Forum. The Pistoia Alliance is a not-for-profit, cross-company organisation committed to lowering the barriers to innovation in Life science R&D. The PRISME Forum is a not-for-profit Pharma R&D IT leadership group focussed on the identification and palliation of “hot topics”, and the sharing of industry best practices.

John has worked in life science R&D informatics in a variety of organizations including academia, the pharmaceutical Industry, a cancer research charity as well as in the technology supply side of the industry.  This has provided him with direct, hands-on experience of delivering computer-based services across the life science R&D value chain.

John graduated in physiology before obtaining a post-graduate certificate in education.

Iain D. Miller


Healthcare Strategies Group

Dr. Iain Miller is the Founder and CEO of Healthcare Strategies Group, which provides strategic advisory and business development support across the Personalized Healthcare spectrum. He has extensive international experience, having split his career between the US and the EU. His client and broader experience base spans GE Healthcare, Biomerieux, J&J, Philips Healthcare, Myriad Genetics, Oxford Immnotec, Abbott Diagnostics and InnovateUK, in addition to various SMEs and investor groups. In addition to his 20-year US experience, Dr. Miller has worked extensively in the UK and EU marketplace, including major market access policy projects with European thought leaders. He is a founding Board member of the European Personalized Medicine Association and has been very active in the UK stratified medicine and broader med-tech ecosystems. Within the UK Iain sits on the NICE Technology Appraisal Committee, which reviews drugs and companion test products, and is a member of the Oxford Bioscience Network Med-Tech Advisory Board. He also frequently serves as an assessor for Innovate UK. In 2012-13, he sat on the Steering Committee of the UK Academy of Medical Sciences Stratified Medicine project, culminating in a major report in July, 2013. Dr. Miller publishes and presents regularly in the field of personalized medicine, including a global review article published in September 2014 and an EU market access analysis report with Epemed in October 2014.

Marie Manley

Partner & Head of the Regulatory Practice


MARIE MANLEY is a Partner and head of the Regulatory Department at Bristows LLP in London.  She advises on IP matters (both contentious and non-contentious), focusing on EU and UK regulatory and competition law in the bio-pharma, chemical, cosmetic, medical devices and food sectors; including life cycle management issues, advertising and product liability.

Marie regularly represents leading bio-pharma companies in litigation before the English and EU courts.  Recently, she successfully represented Laboratoires CTRS before the General Court in two cases: the first, in relation to the Commission’s refusal to grant a marketing authorisation for an orphan medicinal product (Case T-301/12); the second, in relation to the annulment of a competitor marketing authorisation whose SmPC violated the marketing exclusivity protection afforded to the originator’s product (Case T-452/14). Marie also represented Shire Pharmaceuticals to secure a Paediatric extension and Clinuvel Pharmaceuticals to obtain authorisation by the EMA for a breakthrough drug, SCENESSE®, for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP).  [Seattle case is missing and wording about the SPCs case: could you please add this bit in? we have recently added to one of the latest bio.  We need to add this to the web profile as well.... thanks]

Marie also represents pharmaceutical companies before UK and EU institutions (EMA, MHRA, NICE, PMCPA DOH and the European Commission).  For example, she is currently representing a leading pharma company, Les Laboratoires Servier, under investigation by the EU Competition Commission, as well as representing them in an action before the English Courts. Additionally, she has extensive experience in co-ordinating EU and overseas litigation. 

Marie is considered as a leading practitioner for regulatory law and is described by clients as a  ‘truly outstanding regulatory lawyer’ in Who’s who Legal (2015). She was recommended for Life Sciences: Regulatory (Key Individual) - Chambers and Partners (2015/2014/2013), Life Sciences-Regulatory - IP and Product Liability - Who's Who Legal (2013), London Top 100 - London Top 50 Women and EU Law - Super Lawyers UK (2013), Commercial, IP and Regulatory in The Lawyer Hot 100 (2012).

Degrees: LLB Swiss Law, Lausanne University 1991; LLM European Law, Lausanne University 1992; LLM International Law, Columbia University of Law, New York 1995; Postgraduate Diploma EU Competition Law, King’s College, London 2005. Qualified in New York (1998); qualified in England and Wales (2003); Partner 2005. Worked in Switzerland, New York and Brussels. Fluent in English, French and Spanish; working knowledge of German, Italian and Catalan.


Virtue Insight

Virtue Insight equips business professionals around the world with the latest indepth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Our motto is to offer our customers the expertise and connections for a profitable business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business alliances.


Roswell Park Cancer Institute

Roswell Park Cancer Institute (RPCI) is a cancer research and treatment center located in Buffalo, New York, USA. Founded in 1898 by Dr. Roswell Park, RPCI is the nation's first cancer center, and it is the only upstate New York facility to hold the National Cancer Institute designation of "comprehensive cancer center" and to serve as a member of the National Comprehensive Cancer Network. In addition, RPCI is the first dedicated medical facility for cancer treatment and research in the United States. The Institute is involved in drug development and conducts clinical research for cancer treatment.

The campus occupies 28 acres (11 ha) on the 100-acre (40 ha) Buffalo Niagara Medical Campus (BNMC) in downtown Buffalo, and includes 1,500,000 square feet (140,000 m2) of space equally distributed between clinical programs and research/education functions. A hospital building, completed in 1998, houses a diagnostic and treatment center. The campus includes a medical research complex and renovated existing education and research space. RPCI provides advanced treatment for all forms of adult and pediatric cancer, as well as cancer education and research facilities in 15 separate buildings that occupy approximately two million square feet.


Cambridge Biotech



Pharmaphorum is the primary facilitator of thought leadership and innovation within pharma. We support the next generation of pharmaceutical industry leaders through producing, curating and publishing media that will help pharma embrace the challenges of being a healthcare solutions provider in the 21st century.

Our services include:

  • Publication of interesting new written, audio and video content addressing critical pharma issues from around the world.
  • Showcasing key service providers who can work with pharma executives to forge the business models of the future.
  • Curation of global news, industry events and job opportunities within pharma.
  • Production of written, audio and video content for publication on pharmaphorum or client channels.
  • Advice and support on the use of social media within pharma to effectively connect companies, improve PR and share innovation.

Boston Biotech

Lex Witness

LEX WITNESS – India’s 1st Magazine on Legal & Corporate Affairs

LEX WITNESS vows to be a high quality monthly magazine with the powers of fresh and original content that would deal exclusively with subjects pertaining to legality. Country's top notch practitioners and experts are being invited to contribute in WITNESS with what we feel is relevant to all stakeholders in this profession, aiming at brainstorming between the legal luminaries and hence bettering this practice in all its aspects.

Clocate is a leading international directory for worldwide conferences and exhibitions. is equipped with a unique and comprehensive search that helps you find easily any event in any category or location.  Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's  website and more...

If you search for a conference or exhibition in areas such as Industry and manufacturing, Health and medicine, Technology and IT, Business and finance, sciences, education, services (banking, insurance, tourism, Hospitality and more), government, environment, life style and arts, you'll find it in

Going to meet

Partnering with Virtue Insight means more than making the right contacts. It means being an insider. It means being connected to the right people with the right level of influence, and it means you are allied with a globally respected organization and leaders in the industry.?

Sponsorship, exhibiting and advertising packages are designed to provide a solid platform to help you stand out and make an impact. Our programs allow you to achieve your marketing goals and deliver a maximum return on your investment. We have developed convenient and customizable packages to help your organization meet its objectives and reach your target market.

Why Sponsor / Exhibit:

PROFIT: To Maximize
MARKET SHARE: Defending and Increasing Market Share
COMPETITION: To attach and defend against competition


  • Generating sales leads
  • Build brand image
  • Maintaining customer relations
  • Consolidating business relationships
  • Accessing new and emerging markets
  • Obtaining technical knowledge
  • Leverages the events extensive marketing campaign to add value to your organisations marketing strategy and budget leading up to the event
  • Live product demonstration to test market responses
  • Facilitating quick market penetration
  • Reach important targeted commercial prospects face to face in a social, relaxed environment. The ideal platform to build strong business friendships Strengthen your market position

Our conferences offer not only a unique combination of benefits (as listed above) to enable the sponsor/exhibitor to communicate the message but also a major opportunity that other forms of selling or media cannot provide.

Contact Us Today

Email -
Tel: +44-2036120886

Email -
Tel: +91 44 64536444

Our highly researched conference agenda delivers all the latest information and our world-class speakers attract delegates from around the world to attend. We aim for our attendees to be equipped with knowledge of latest developments and enable them to network with the industry key personnel.

What is the format of our conference programme?
The conference programme consists of world-class keynote addresses, case study presentations and panel discussions.

What are the benefits of attending?

  • Meet your peers in an interactive, discussion-based format designed to maximize knowledge transfer and networking
  • Enjoy our informal networking at drinks and lunch
  • Meet the leading solution providers in the market to forge partnerships and discover solutions
  • Receive electronic versions of the conference documentation for use of reference post-event.
  • Get ideas for?training topics?that you might want to present as professional development sessions to others in your workplace.
  • Observe speakers from the perspective of seeing what works really well so you can learn new public speaking techniques and strategies that you can apply when doing your own presentations.
  • Learn what not to do in presentations if you end up sitting through any sessions that fail to be engaging or informative.
  • Delegates also benefit from discounted rates onfuture event attendance

For more information or to register at the event please contact us TODAY:

Contact Us Today

Email -
Tel: +44-2036120886

Email -
Tel: +91 44 64536444


Introductory Offer (3 delegate places for the price of 2):- A huge saving of £1100 - (Limited seats left) - You can simply email or call and book your conference delegate seats on – TEL: +44 2036120886. Email – 


Standard Registration (9th November 2015 Onwards):- Conference Delegate Pass (£1100 + VAT per delegate) – You can simply email or call and book your conference delegate seats on – TEL: +44 2036120886. Email –


Conference Sponsor & Exhibition Stall – Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to – TEL: +44 2036120886. Email –

Pestana Chelsea Bridge Hotel & Spa

Address: 354 Queenstown Rd, London SW8 4AE, United Kingdom
Phone:+44 20 7062 8000

Should you wish to book your rooms in the same conference hotel for your stay during the conference nights, pelase make use of our special rates taht has been provided by the hotel. To book your rooms - Click here

No testimonial available..

DOWNLOAD Andreas Benesic_MetaHeps
DOWNLOAD Hans Lehrach_Max-Planck Institute for Molecular Genetics
DOWNLOAD Iain D. Miller_Healthcare Strategies Group
DOWNLOAD John Wise_Pistoia Alliance
DOWNLOAD Michael Merz_Novartis
DOWNLOAD Peter Demant_Roswell Park Cancer Institute
DOWNLOAD Philipp Schatz_Metanomics Health
DOWNLOAD Richardus Vonk_Bayer
DOWNLOAD Steinar Madsen_Norwegian Medicines Agency
DOWNLOAD Stephen Pennington_University College Dublin
DOWNLOAD Suzanne Jenkins_AstraZeneca

Conference pictures can be viewed and downloaded at our official Virtue Insight facebook page

Link - Click Here

You have been registered successfully!
Enter Password
Submit Close